Considering the vascular factor in the progression of diabetic neuropathy, we investigated the effect of a thromboxane synthetase inhibitor on the peripheral nerve function and skin blood flow of diabetics with neuropathy to determine wthether it had any effect on the diabetic neuropathy.
Fourteen diabetic patients with neuropathy were treated with the thromboxane synthetase inhibitor CV 4151 for 8 weeks and examined for changes in nerve conduction velocity (NCV), vibratory perception threshold (VPT), skin blood flow measured with a laser Doppler flow meter, deep skin temperature in the extremities, and changes in plasma thromboxane B
2 (TXB
2) and plasma 6-keto-prostaglandin F
1α (6-keto-PGF
1α). After administration of CV 4151, plasma TXB
2 levels decreased, and plasma 6-keto-PGF
1α-levels increased significantly. As a result, the plasma TXB2/6-keto-PGF
1α, ratio dropped significantly to a lower level than before treatment. NCV and VPT in the extremities improved significantly, as did deep skin temperature and skin blood flow. The degree of improvement in motor nerve conductin velocity in the lower extremities, of deep skin temperature in the lower extremities, and of skin blood flow in the lower extremities were significantly intercorrelated. Treatment of diabetics with thromboxane synthetase inhibitor appears to decrease TXA
2 production and increase PGI
2 production, improving the TXA
2/PGI
2 ratio; as a result, skin blood flow increases and nerve functions improve.
In conclusion, thromboxane synthetase inhibitors which improve the TXB
2/PGI
2 ratio and blood flow can be used in the treatment of diabetic neuropathy.
View full abstract